Respiratory syncytial virus (RSV) is a common germ that can settle into your lungs and airways. It's the top cause of upper respiratory infection in babies and toddlers, but anyone can get it. While ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease ...

Learn how to identify RSV symptoms in adults, how to know if an RSV infection has become serious, how to avoid RSV, and whether to get an RSV vaccine.

Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...

Thursday, Pfizer Inc (NYSE:PFE) announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the ...

While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...

“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the ...

*The vaccine efficacy is estimated using a Poisson model adjusted by age, region and season. A similar pattern of vaccine efficacy over two seasons was also observed in adults with underlying ...

Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and ...